OBJECTIVES:: In Colombia, the use of Hematopoietic stem cell transplantation (HCT) as a treatment for myeloma, Hodgkin’s, non-Hodgkin’s lymphoma, acute lymphoblastic leukemia, and acute myeloid leukemia, has increased. This study aimed to evaluate potential disparities and barriers in access associated with this complex treatment modality. METHODS:: Data from all of Colombia’s 33 departments were used in this study. HCT centers were extracted from Colombia’s Administrative Cancer Registry (Resolution 247/2014), street addresses for HCT centers were obtained from the registry of health care providers and searched for spatial coordinates. Data for patients transplanted were obtained from the High-Cost Disease Office (Fondo Colombiano de Enfermedades de Alto Costo) and located by their municipality of residence. RESULTS:: In the observed data 7 of 14 HCT Colombian centers had data between January 2, 2014, to January 1st of 2015. There was a population of 16.778 diagnosed with hematological malignancies. Of these patients, 395 received an HCT among those seven facilities. For these patients, the median distance to a treatment center was 142 km and spent an average of 172 minutes to arrive at their HCT center. The median distance was 132 km for patients with private insurance and 267 km for patients with subsidized insurance. Approximately 50% of patients who live in a municipality without an HCT Center have access within a travel time of 248 minutes and 75% within 484 minutes. CONCLUSIONS:: Distance and time are important determinants of access to health-care systems. It is the first study to assess these variables as they relate to access to HCT in Colombia. We found that travel time and distance can be linked to the patients’ residence zone. Additionally, in three of the five most populated municipalities in Colombia, travel time and distance were the lowest, while the populations with smaller populations had the largest travel times and distances.